Cancer diagnostics innovator OneCell Diagnostics has successfully raised $16 million in its Series A funding round. The round was led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
The funding will be directed toward scaling operations in the US market for its flagship product, OncoIndx Alfa. This advanced liquid biopsy test identifies circulating tumor cells, offering a cutting-edge solution in cancer diagnostics, as shared by the company.
Launched in 2021, OneCell Diagnostics leverages next-generation sequencing, artificial intelligence, machine learning, and robust data analytics to create multi-omics biomarkers. The innovative approach positions the company as a leader in precision cancer diagnostics.
“Our vision is to make life-saving cancer testing accessible to everyone, and this funding validates our commitment,” shared Mohan Uttarwar, CEO and co-founder of OneCell Diagnostics.
OncoIndx Alfa provides advanced biomarkers to enhance precision diagnosis and treatment of cancer. Its capabilities include monitoring treatment response, tracking disease progression, identifying recurrence, and more.
OneCell Diagnostics has also formed strategic collaborations with esteemed institutions such as All India Institute of Medical Science (AIIMS), New Delhi, and Tata Memorial Centre. It partners with academic giants like Harvard Medical School and Stanford University to further its mission.
The company has tested its cell biopsy technology on nearly 10,000 patients in India and continues to develop new products to transform cancer care globally.
4o